We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in TCR2 Therapeutics Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 59 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 59 → 0 (-59)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

100% less capital invested

Capital invested by funds: $31.4M → $0 (-$31.4M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 59

Holders
–
Holders Change
-59
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
59
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
MAM
MPM Asset Management
Massachusetts
-$6.08M
2
TCM
Tang Capital Management
California
-$5.1M
3
MB
MPM BioImpact
Massachusetts
-$5.06M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.2M
5
NM
Newtyn Management
New York
-$1.52M
Name Holding Trade Value Shares
Change 		Change in
Stake
T. Rowe Price Associates
26
T. Rowe Price Associates
Maryland
– -$74K -48,900 Closed
SC
27
Sagefield Capital
Texas
– -$65.8K -43,900 Closed
Wells Fargo
28
Wells Fargo
California
– -$61K -40,688 Closed
OC
29
Oppenheimer & Co
New York
– -$56.9K -37,950 Closed
GCP
30
GSA Capital Partners
United Kingdom
– -$56K -37,452 Closed
Two Sigma Investments
31
Two Sigma Investments
New York
– -$54K -36,000 Closed
Barclays
32
Barclays
United Kingdom
– -$49.7K -33,116 Closed
XSC
33
X-Square Capital
Puerto Rico
– -$48K -31,720 Closed
Millennium Management
34
Millennium Management
New York
– -$48K -31,683 Closed
Commonwealth Equity Services
35
Commonwealth Equity Services
Massachusetts
– -$37 -24,973 Closed
Charles Schwab
36
Charles Schwab
California
– -$34K -22,638 Closed
Bank of America
37
Bank of America
North Carolina
– -$31.7K -21,166 Closed
HSBC Holdings
38
HSBC Holdings
United Kingdom
– -$25.5K -17,257 Closed
Bank of New York Mellon
39
Bank of New York Mellon
New York
– -$19.1K -12,755 Closed
NDSI
40
Newman Dignan & Sheerar Inc
Rhode Island
– -$18.8K -12,522 Closed
IFG
41
Independent Financial Group
California
– -$18.1K -12,075 Closed
HF
42
HRT Financial
New York
– -$16K -11,024 Closed
Goldman Sachs
43
Goldman Sachs
New York
– -$16.1K -10,765 Closed
TRCT
44
Tower Research Capital (TRC)
New York
– -$11K -7,678 Closed
Federated Hermes
45
Federated Hermes
Pennsylvania
– -$10.6K -7,081 Closed
LC
46
Lindbrook Capital
California
– -$4.58K -3,050 Closed
Osaic Holdings
47
Osaic Holdings
Arizona
– -$2.7K -1,801 Closed
Simplex Trading
48
Simplex Trading
Illinois
– -$2K -1,444 Closed
CG
49
Cutler Group
California
– -$1K -1,000 Closed
HWM
50
HighMark Wealth Management
Minnesota
– -$1.26K -840 Closed
1
2
3

TCRR Hedge Fund Activity: Q2 2023 in Review

0 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q2 2023, worth a combined $0 — down 100% from $31.4M a quarter earlier.

Sellers outnumbered buyers: 59 funds closed out of TCRR and 0 opened new positions — a net loss of 59 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was MPM Asset Management, exiting entirely with an estimated $6.08M sold.

  • 0 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q2 2023, down from 59 in Q1 2023.
  • Funds reported $0 of TCR2 Therapeutics Inc. Common Stock stock for Q2 2023, down 100% quarter-over-quarter.
  • 0 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q2 2023 and 59 closed out, a net change of -59 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q2 2023 was MPM Asset Management, an estimated $6.08M sold.

Based on aggregated 13F filings for Q2 2023.